SGIOF - Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript

2025-01-31 22:53:33 ET

Shionogi & Co., Ltd. (SGIOY)

Q3 2024 Earnings Conference Call

January 31, 2025 03:30 AM ET

Company Participants

Yoshimasa Kyokawa - VP, Corporate Communications

Masako Kudou - VP, Finance & Accounting Department

Kazuhiro Hatanaka - Senior Executive Officer, Corporate Supervisory Unit & Corporate Strategy Division

Toshinobu Iwasaki - SVP, Healthcare Business Unit

Takeki Uehara - SVP, Drug Development & Regulatory Science Division

Conference Call Participants

Hidemaru Yamaguchi - Citi

Eiji Ueda - Goldman Sachs

Fumiyoshi Sakai - UBS

Kazuaki Hashiguchi - Daiwa Securities

Shinya Tsuzuki - Mizuho Securities

Shinichiro Muraoka - Morgan Stanley

Seiji Wakao - JPMorgan

Presentation

Yoshimasa Kyokawa

This is Kyokawa of the Corporate Communication Department of Shionogi. Thank you very much for gathering today. From now, we would like to begin the presentation of the Third Quarter of Fiscal 2024 Financial Results from Shionogi & Co., Ltd..

First of all, let me introduce the people who are here with us. First of all, Toshinobu Iwasaki, Senior Executive Officer, Healthcare Business Supervisory Unit. Next, Koji Hanasaki, Senior Executive Officers of Supply, Supervisory Unit. And next is, Kazuhiro Hatanaka, Senior Executive Officer, Corporate Supervisory Unit and Corporate Strategy Division And next is, Takiki Uehara, Corporate Officer of Drug Development and Regulatory Science Division. [indiscernible] is joining from different venue online. And, we have, Masako Kudou from the Finance and Accounting Department.

Let me briefly explain the flow of today's meeting. First of all, we would like to give you the overview of the Q3 FY ‘2024 financial results and transformation of Chinese business and pipeline progress will be explained, and we will have Q&A session after that. We will have a simultaneous interpretation service for this meeting. So if you are going to use the translation, please press the globe icon and select language you wish to listen to.

Now let us begin. Q3 FY ‘2024 financial results. Ms. Kudou, please.

Masako Kudou

Yes. I’d like to give through the overview of the Q3 FY 2024 financial results. First on Page 4, this is the highlight of financial results. Sales revenue was JPY333.6 billion, down JPY3.2 billion from last year's JPY336.8 billion. However, excluding the one-time payment of JPY25 billion associated with the license transfer of an ADHD drug that was recorded in the first quarter of last year, revenue increased by JPY21.8 billion, due to the significant growth of royalty income and overseas business as well as the stabilization of our domestic business. In addition, for the same reason, operating profit increased by JPY15.5 billion, excluding the one-time payment....

For further details see: